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Abstract
Background: Stent length serves as a predictor of restenosis in use of bare metal stents (BMS).
This has been demonstrated in a feasibility study that used a single short BMS implant (<9 mm) in
a high proportion of lesions; the study observed a low rate of restenosis.
Methods: We performed a pilot prospective study to investigate in a series of consecutive patients
the immediate and long-term effects of implantation of either 1) a single short BMS for all lesions
with low probability of restenosis or 2) a drug-eluting stent (DES) for all other lesions.
Results: The 200 patients studied had 236 coronary artery lesions that were treated with short
BMS in 168/236 patients (71.2%) and with DES in 68/236 patients (28.8%). Angiographic success
was achieved in 230/236 lesions (97.5%) and procedural success in 194/200 patients (97.0%).
Restenosis occurred in 15/153 lesions (9.8%) after short BMS, in 3/62 lesions (4.8%) after DES, and
in 18/215 of all lesions (8.4%) angiographically controlled after six to eight months. Target vessel
revascularization was performed in 16/218 lesion (7.4%).
Conclusion: Most of the coronary artery lesions in this small group of consecutive patients were
treated sufficiently with a single BMS implant. This differential approach of treating suitable lesions
in medium- to large-sized vessels with a single short BMS device and treating all other lesions with
a DES implant resulted in a low incidence of restenosis.
Introduction
Sirolimus- and Tarcolimus-eluting stents reduce resteno-
sis rates in larger vessels and in longer lesions as compared
to bare metal stents (BMS) [1,2]. The low restenosis rates
found with these drug-eluting stents (DES) suggests that
all lesions could benefit from this type of stent. One con-
cern about their use in the majority of lesions relates to
cost, since these stents are much more expensive than bare
metal stents [2]. A recently published cost-effectiveness
analysis showed that treatment with DES would impart
cost savings in patients with a BMS target vessel revascu-
larization (TVR) rate >20% and cost effectiveness in
patients with a BMS TVR rate >12% [3]. Stent length and
vessel size represent primary factors affecting BMS resten-
osis rates [4]. Moreover, implantation of a BMS that is
longer than the lesion itself increases the risk of restenosis
independently [5].
In a previous prospective study, we demonstrated that
stenting of only the most significant obstruction of a
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lesion after balloon dilatation or use of direct stenting
alone was feasible in a high proportion of cases yielding
low rates of stenosis. [6]. In another prospective study, we
observed that short stenting significantly reduced the res-
tenosis rate as compared to conventional stenting, which
involves placement of the stent over the entire stenotic
segment of a vessel [7]. In this latter study, vessel size only
was found to predict restenosis after short stenting. In the
present pilot study, we report on our ongoing evaluations
by comparing a) short stenting with BMS in lesions with
low probability of restenosis to b) stenting with DES in
lesions with predicted restenosis rates of >10% after BMS.
Methods
Patients
Two hundred consecutive patients with symptoms of
angina pectoris, a positive exercise tolerance test, or both,
and coronary arteries with >60% diameter stenoses were
included in this study. Patients with lesions in the left
main artery and patients treated for myocardial infarction
were excluded.
Procedures
Clopidogrel 75 mg was administered daily starting 4 days
prior to elective interventions. All patients received acetyl-
salicylic acid for at least 14 days prior to intervention and
heparin (5000 IU) as an intravenous bolus before the pro-
cedure and then by infusion during the procedure, at dose
levels targeting a 2.5-fold prolongation of activated pro-
thrombin time (aPTT). Percutaneous transluminal coro-
nary angioplasty was performed initially in most cases
using semi-compliant balloons. The balloon length was
15 mm for short lesions (<10 mm) and 20 mm for longer
lesions. Balloon sizes were selected to achieve a balloon/
artery ratio of 1.0 to 1.2 when fully expanded at >10 atm.
Use of BMS stents
A short BMS (<10 mm) was considered for vessels > 2.7
mm, to be implanted either:
1. By direct stenting if the lesion had a length <10 mm
located in the proximal part of the left anterior descending
coronary artery, or of the right coronary artery; or
2. After balloon dilatation of a longer lesion if angiogra-
phy performed 5 min after the initial intervention showed
a residual stenosis >30% that reflected a lesion ≤ 10 mm
in length, in the absence of a longer dissection.
Use of DES stents
For all other lesions not suitable for a short BMS, a DES
was implanted.
All stents, premounted on semi-compliant balloons, were
sized to achieve a stent to artery ratio of 1.1 at >12 atm.
The short BMS included 168 MultiLink stents, while the
DES involved 53 Cypher stents and 15 Taxus stents. After
the procedure, all patients were prescribed acetylsalicyclic
acid 100 mg daily indefinitely. For patients who had
received a stent, clopidogrel 75 mg daily was also pre-
scribed for 4 weeks. Patients with hypercholesterolemia
were strongly advised to take a cholesterol synthesis
inhibitor regularly. Six months and eight months after
implantation of the BMS and DES implants, respectively,
control angiography was performed using projections that
were identical to those employed during the intervention.
Quantitative coronary angiography
The CAAS II Research System (Pie Medical Imaging, Maas-
tricht, The Netherlands) was used for automated contour
detection and quantification. The system and validation
data are described elsewhere [8]. The measurement proce-
dure was previously published in detail [9]. Angiography
was performed before and after all interventions and at
angiographic follow-up using identical projections and
analyses. Frames were selected as recommended by Her-
rington and Walford [10]. Analyses followed the guide-
lines proposed by Reiber et al. [11]. Lesion length was the
distance along a vessel segment characterized by a diame-
ter stenosis >50%, as compared to the reference segment.
Lesion length, mean diameter within the lesion (mean
stenosis diameter), and minimum lumen diameter
(MLD) were calculated for the target vessel segment. In
addition, mean diameter stenosis and minimum lumen
diameter were measured at a distance of 5 mm from each
stent edge. Restenosis was defined as > 50% in segment
diameter stenosis at angiographic follow-up.
Statistical analyses
Continuous data are expressed as the mean ± the standard
deviation. Chi-square tests were used to compare categor-
ical variables, and the Mann-Whitney test was employed
to compare continuous variables. Statistical significance
was accepted at p<0.05.
Results
The study included 200 consecutive patients with a total
of 236 treated lesions (mean 1.2 lesions/patient). Baseline
clinical and angiographic characteristics are shown in
Tables 1 and 2. Balloon dilatation was performed initially
in 198/236 (83.9%) coronary artery lesions, and direct
stenting with a short BMS was performed in 38/236
(16.1%). A short BMS after balloon angioplasty was
judged suitable in 130/236 (55.1%) lesions, and a DES
was implanted in 68/236 (28.8%) lesions that were
deemed to be unsuitable for BMS. An additional stent was
implanted subsequent to the first procedure in cases
involving persistent residual stenosis >30% or a dissection
in nine cases (5.4%). Three DES implants could not beCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:18 http://cvm.controlled-trials.com/content/6/1/18
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deployed; the results of the balloon angioplasty were not
further manipulated.
As compared to BMS implantation, DES implants were
used more frequently for side branch lesions (p = 0.03)
and longer lesions (p<0.0001) in smaller vessels (p  =
0.0001). The DES devices were significantly smaller (2.7 ±
0.2 mm vs. 3.0 ± 0.4 mm, p < 0.0001) and longer (18.4 ±
5 mm vs. 8.3 ± 0.2 mm, p < 0.0001) than the short BMS
implants (Table 3).
Angiographic analysis revealed that residual plaque out-
side the short BMS contributed to 25% to 45% residual
diameter stenosis in 15/168 (8.9%) lesions, and none
after DES implantation.
Immediate results
Angiographic success (post-intervention diameter <30%
within the stent) was the same for short BMS and DES
(164/168; 97.6%, and 66/68; 97.0%) as was procedural
success (angiographic success and no MACE [myocardial
infarction, reintervention, death]), which was accom-
plished in 194 /200 (97.0%) patients (Table 4). Major car-
diac events (myocardial infarction, repeat target vessel
revascularization or death) occurred in two patients.
Clinical follow-up
Angina pectoris (Canadian Cardiovascular Society classes
III or IV) recurred during follow-up in 3 patients, and
major cardiac events were experienced by 3 patients, of
whom 2 died during the 8-month follow-up period while
the third underwent elective coronary artery bypass graft-
ing. Target vessel revascularization was performed in 16/
218 (7.4%) lesions at follow-up.
Angiographic follow-up
In 180/192 eligible patients, angiography was repeated at
193 ± 25 days on 215/226 (95.1%) lesions (Table 5). Res-
tenosis occurred in 18/215 (8.4%) of all lesions, in 15/
153 (9.8%) lesions treated with a short BMS and in 3/62
(4.8%) lesions after DES. According to univariate analysis,
the restenosis rate was higher when an additional stent
had been implanted after short BMS. No other clinical or
angiographic parameter was associated with increased risk
of restenosis.
Discussion
Although BMS implants in many lesions have reduced the
restenosis rate as compared to PTCA, stent implantation
in the clinical setting continues to yield restenosis rates
exceeding 20% [12]. In general, in-stent restenosis (ISR)
can be predicted based on stent size and stent length and
based on the presence of diabetes mellitus [4,13]. Previ-
ous analyses have demonstrated that stent length can
serve as a predictor of ISR independent of lesion length
[14,15]. A recent meta-analysis of intervention trials
noted that stent length exceeds lesion length in about
90% of interventions; this excess in stent length increased
the risk of ISR independent of other parameters in bare
metal stenting [5].
In a previous study investigating the feasibility of rou-
tinely shortening stent length to cover only those vessel
segments with significant obturating plaque and leaving
nonobstructing plaque material unstented, we found it
suitable to use a single stent <10 mm in 60% of all stent
implantation procedures [6]. The 6-month angiographic
restenosis rate in this study was 16% for all stented
lesions. In a prospective study of 400 consecutive patients
who underwent short stenting of their coronary artery
lesions, we compared immediate and long-term results
with a matched-pair control group of patients treated ear-
lier with conventional-length stents. We found a signifi-
cantly lower restenosis rate after short stenting, with no
difference in the procedural success rates [7]. Vessel size
was the only predictor of ISR after short stenting. In 91%
of all lesions stented, the TVR rate was <10% in all vessels
>2.7 mm.
Table 2: Lesion baseline characteristics
Variable All lesions N = 236
De novo lesion 227 (94.9%)
Total occlusion 8 (3.4%)
Left anterior descending artery 83 (35.2%)
Left circumflex artery 53 (22.5%)
Right coronary artery 73 (30.9%)
Coronary artery side branches 23 (9.7%)




AHA type A/B1 93 (39.4%)
AHA type B2/C 143 (60.6%)
AHA: American Heart Association.
Table 1: Baseline characteristics
Variable All patients N = 200
Age (years) 62 ± 10
Males 154 (77.0%)
CCS III – IV 78 (38.0%)
Hypertension 153 (76.5%)
Hypercholesterinemia 155 (77.5%)
Diabetes mellitus 48 (24.0%)
Multivessel coronary disease 97 (48.5%)
± : Standard deviation.
CCS: Canadian Cardiovascular Society classification.Current Controlled Trials in Cardiovascular Medicine 2005, 6:18 http://cvm.controlled-trials.com/content/6/1/18
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With the routine use of drug-eluting stents, a lower reste-
nosis rate can be anticipated. However, the costs of rou-
tine use of DES implants are high. A recent cost-
effectiveness analysis for DES showed that these devices
are cost effective when the TVR rate of BMS exceeds 12%
[3].
The present pilot study was designed to demonstrate the
feasibility of using short stenting in lesions with a < 10%
probability of restenosis and implanting DES in all other
lesions. In keeping with the results of the former investi-
gation, a single short BMS was sufficient in the majority of
interventions (252/310, 81.3%). There was a nearly 1:1
match of the stent and the lesion length. The resulting res-
tenosis rate was within the range found in larger trials for
the given stent dimensions used [13,16].
Our protocol included percutaneous transluminal coro-
nary angioplasty as the initial procedure for most lesions.
Balloon dilatation alone achieved a low residual stenosis
in only a few lesions; however, it did reduce the length of
obturating plaques responsible for diameter stenoses
>30%. This shortening of the significant portions of the
lesions contributed to the high number of lesions that
could be treated adequately with single short stents. In
5.4% of these lesions, however, their length was underes-
timated or a stent was misplaced, thereby requiring an
additional stent, which contributed to restenosis found in
the short BMS group. Plaques that were adjacent to a BMS
and that caused luminal narrowing < 45% exhibited no
increased frequency of restenosis. This finding is consist-
ent with previous investigations, in which incomplete
plaque coverage was not associated with increased risk for
restenosis.
In conjunction with the strategy of incomplete plaque
coverage, Colombo et al. introduced the concept of 'spot
stenting' long lesions (>15 mm). These researchers com-
pared a) complete coverage of a treated long lesion to b)
stenting only those stenosis segments that did not meet
pre-defined intravascular ultrasound criteria for successful
treatment after initial balloon dilatation [17]. They
observed a lower restenosis rate in the latter group.
Indeed, restricting stent surface to the minimum necessary
area might reduce proliferative responses of the arterial
wall to the stent [18,19].
Our findings regarding DES are comparable to those from
a larger investigation of more complex lesions [1]. The
overall restenosis rate of 8.4% and the TVR rate of 7.4%
noted with the differential use of short bare metal stenting
and DES implantation raises the question of use of DES
implantation in all lesions, in terms of economic consid-
erations. Moreover, none of the observed restenoses were
diffuse or proliferative after single short BMS, a finding
that is compatible with a high long-term success rate after
reintervention [20].
Methodological aspects
An exact determination of lesion length was crucial to the
interpretation of angiographic results. The criterion used
to measure lesion length by quantitative angiography
(length of plaque causing >50% diameter reduction)
reflects more precisely the extent of clinically relevant
stenoses and makes it possible to standardize measure-
ments, in contrast to overall lesion length as used by many
automated contour detecting systems. However, lesion
length as measured by the criterion described above is
Table 3: Procedural data and baseline characteristics of quantitative coronary angiography
Variable Short BMS n = 168 DES n = 68 p All Stents n = 236
Stent length (mm) 8.3 ± 0.2 18.4 ± 5 <0.0001 11.2 ± 8
Nominal device diameter (mm) 3.0 ± 0.4 2.7 ± 0.2 <0.0001 2.9 ± 0.5
Inflation pressure (atm) 13 ± 3 13 ± 3 ns 13 ± 3
Device/artery ratio 1.12 ± 0.1 1.14 ± 0.1 ns 1.13 ± 0.1
Reference diameter (mm) 3.1 ± 0.4 2.8 ± 0.3 <0.0001 3.0 ± 0.5
Diameter stenosis before (%) 74 ± 14 76 ± 13 <0.0001 75 ± 14
MLD before (mm) 0.77 ± 0.4 0.73 ± 0.4 ns 0.76 ± 0.3
Plaque area (mm2) 9 ± 5 14 ± 7 0.0001 10 ± 6
Lesion length (mm) 8.7 ± 3 14.6 ± 5 <0.0001 9.8 ± 5
Nominal device diameter: Stent diameter at nominal inflation pressure.
± : Standard deviation.
ns: non-significant.
MLD: Mean lumen diameter.
Table 4: Clinical and angiographic outcomes
Variable All lesions n = 236
Angiographic success 230 (97.5%)
Procedural success 194/200 (97.0%)
Final minimum lumen diameter (mm) 2.9 ± 0.3
Final diameter stenosis (%) 15 ± 12
Acute gain (mm) 2.2 ± 0.3
Final plaque area (mm2) 2.8 ± 2.2Current Controlled Trials in Cardiovascular Medicine 2005, 6:18 http://cvm.controlled-trials.com/content/6/1/18
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usually shorter, as compared to measuring total lesion
length. Since the present study was not designed to com-
pare immediate and long-term results of short BMS and
DES, we did not perform statistical comparative analysis.
Limitations
Our criteria for selecting a short BMS implant versus a DES
implant for study participants were based on results from
a non-randomized study performed earlier at our institu-
tion [7]. Selection of the stent device was based on opera-
tors' visual interpretation of vessel dimensions. This may,
in a few cases, have led to misinterpretation of the actual
reference diameter, as demonstrated by quantitative coro-
nary angiography. In these cases, the other stent device
was, therefore, implanted. Finally, the study was not ran-
domized, since we intended to prove feasibility of the dif-
ferential approach in a pilot study. A randomized
multicenter trial now seems suitable to elucidate compat-
ibility and cost-effectiveness of this approach with routine
DES implantation.
Conclusion
We demonstrated that: 1) for most lesions, a single short
BMS is sufficient to treat the significant part of the stenotic
lesion, and 2) the resulting restenosis rate using the single
short BMS is low if vessels > 2.7 mm are treated. Use of
DES for all other lesions that could not be treated suffi-
ciently with a short BMS also resulted in a low restenosis
rate. These findings suggest a positive synergism between
short bare metal stenting and drug-eluting stenting, in
terms of reducing costs while achieving overall low reste-
nosis rates in unselected lesions.
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